Objectives HLA alloimmunization is one of the most troublesome consequence of regular
transfusion which is itself a mainstay measure to provide longevity to the thalassemia …

Background Transfusion is a lifesaving treatment for lots of patients. However, in chronic
blood recipients such as thalassemia patients, there are high concerns about alloantibody …

Thalassemia is the most common inherited singlegene disorder, causes by decrease or
absence of α-globin or β-globin chain production. The disorder commonly inherited in …

Abstract Background and Objective: The mainstay of management of severe β-thalassemia
remains lifelong blood transfusion. The development of one or more alloantibody against …

SUMMARY Background and Objectives Recently, thalassemia has been introduced as a
chronic disease. In spite of prolonging life in thalassemia patients, the quality of their life has …

Background: Thalassemia is one of the most common monogenic disorders characterized
by reduced production of globin chains. Although regular red blood cell (RBC) transfusion …

BACKGROUND: Thalassemia is one of the most common congenital hemoglobinopathies
globally. Regular red blood cell (RBC) transfusion is of paramount importance in the …

Background: Patients with thalassemia major are clinically dependent on red blood cell
(RBC) transfusions. Performing multiple transfusions increase the risk of transfusion-related …

BACKGROUND β‐Thalassemia is considered the most common chronic hemolytic anemia
in Egypt. Alloimmunization can lead to serious clinical complications in transfusion …

Background: Transfusion is the mainstay treatment of patients with thalassemia major and
occasionally in thalassemia intermediate. Alloimmunization is an unwanted side effect of …